A number of other analysts also recently issued reports on the stock. Zacks Investment Research raised shares of HUTCHISON CHINA/S from a “sell” rating to a “hold” rating in a report on Wednesday, April 17th. HSBC began coverage on shares of HUTCHISON CHINA/S in a report on Wednesday, March 27th. They issued a “buy” rating for the company. Finally, Deutsche Bank began coverage on shares of HUTCHISON CHINA/S in a research report on Monday, March 4th. They set a “buy” rating and a $26.82 price objective for the company. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. HUTCHISON CHINA/S currently has a consensus rating of “Buy” and a consensus price target of $26.82.
Shares of HCM stock traded down $0.24 during midday trading on Monday, hitting $27.20. 392,731 shares of the company were exchanged, compared to its average volume of 159,845. The company has a market capitalization of $3.55 billion, a price-to-earnings ratio of -47.72 and a beta of 1.10. The company has a debt-to-equity ratio of 0.06, a quick ratio of 4.19 and a current ratio of 4.33. HUTCHISON CHINA/S has a 52 week low of $20.83 and a 52 week high of $39.68.
About HUTCHISON CHINA/S
Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in discovery, development, and commercialization of targeted therapeutics and immunotherapies for oncology and immunological diseases in the People's Republic of China and Hong Kong. The company operates through Innovation Platform and Commercial Platform segments.
Read More: Why Invest in Dividend Achievers?
Receive News & Ratings for HUTCHISON CHINA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHISON CHINA/S and related companies with MarketBeat.com's FREE daily email newsletter.